Invivyd Inc

The stock IVVD is in a Stage 4 decline with a confirmed series of lower highs and lower lows below declining EMAs, supported by distribution volume dominance. Medium-term directional bias is bearish, and near-term pullbacks into the 9/21 EMAs create favorable sell-side entry opportunities. While RSI shows extreme oversold readings, the lack of mean-reversion eligibility and failure of rallies at EMAs suggest downward momentum remains intact. We recommend immediate bearish engagement at resistance zones around the 9/21 EMAs.

• ↑Pemgarda net revenue rose 21% YoY to $14.3M in Q2 2026.
• ↑$226.7M cash position supports Phase III VYD2311 trial.
• ↓FDA flagged mixed third-party data in Pemgarda fact sheet.